CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
Fluarix™biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00706563
NCT00706563Phase 3Completed
CompareCT.gov

A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in People Aged 18 Years or Above

GlaxoSmithKline·interventional·Posted Jun 27, 2008·Updated Aug 17, 2018

In Brief

A Phase 3 clinical trial evaluating Fluarix™ for Influenza. Completed, enrolled 120 participants across 5 sites.

Detailed Summary

This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2008-2009 season.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2008
Enrollment StartJul 7, 2008
Primary CompletionJul 30, 2008
TodayJul 2, 2026
Enrollment to primary: 23 daysPosted 18.0 years ago

Interventions

Fluarix™biological

Single intramuscular dose on Day 0